A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

BACKGROUND: Albaconazole is a novel triazole being developed for the oral treatment of fungal diseases. Once-weekly oral dosing with 400 mg albaconazole for 24 or 36 weeks resulted in high rates of clinical and mycological resolution for distal subungual onychomycosis, as well as a favorable safety...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rossem, Koen, Lowe, Jenny A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564460/
https://www.ncbi.nlm.nih.gov/pubmed/23390369
http://dx.doi.org/10.2147/CPAA.S39600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564460/
https://www.ncbi.nlm.nih.gov/pubmed/23390369
http://dx.doi.org/10.2147/CPAA.S39600

Ejemplares similares